Amgen Inc. $AMGN Shares Sold by Colton Groome Financial Advisors LLC

Colton Groome Financial Advisors LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 78.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 970 shares of the medical research company’s stock after selling 3,524 shares during the period. Colton Groome Financial Advisors LLC’s holdings in Amgen were worth $409,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Rosenberg Matthew Hamilton increased its holdings in shares of Amgen by 3.9% in the third quarter. Rosenberg Matthew Hamilton now owns 1,474 shares of the medical research company’s stock worth $621,000 after acquiring an additional 55 shares in the last quarter. Park National Corp OH grew its position in shares of Amgen by 7.9% in the 3rd quarter. Park National Corp OH now owns 2,442 shares of the medical research company’s stock valued at $1,029,000 after purchasing an additional 179 shares during the period. Ferguson Wellman Capital Management Inc. grew its position in shares of Amgen by 4.8% in the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 259,022 shares of the medical research company’s stock valued at $103,614,000 after purchasing an additional 11,950 shares during the period. Eastern Bank increased its stake in Amgen by 1.7% during the 3rd quarter. Eastern Bank now owns 4,525 shares of the medical research company’s stock worth $1,907,000 after purchasing an additional 76 shares in the last quarter. Finally, Heartwood Wealth Advisors LLC raised its holdings in Amgen by 1.2% during the 3rd quarter. Heartwood Wealth Advisors LLC now owns 5,216 shares of the medical research company’s stock worth $2,199,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on AMGN. TD Cowen raised their price objective on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating and set a $450.00 target price on the stock. in a report on Tuesday, September 8th. Canaccord Genuity Group increased their price target on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Amgen in a report on Monday. Finally, Weiss Ratings raised shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $385.25.

Amgen Price Performance

NASDAQ:AMGN traded down $1.18 during trading hours on Tuesday, reaching $401.80. 729,172 shares of the company were exchanged, compared to its average volume of 2,754,507. The business has a 50 day moving average of $411.25 and a 200 day moving average of $370.65. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company has a market capitalization of $217.23 billion, a P/E ratio of 24.94, a P/E/G ratio of 2.91 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the firm posted $6.02 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.